Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Clinical trial NCT03881735 · WITHDRAWN

Trial details

NCT number: NCT03881735
Sponsor: Roswell Park Cancer Institute
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Blasts Under 5 Percent of Peripheral Blood White Cells Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level IDH2 Gene Mutation Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

Start date: 2019-12-02
Primary completion: 2021-11-19
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.